| Ocular Findings Before and After Pegylated Interferon Treatment in Chronic Hepatitis B and C Patients | ŞÜKRAN KÖSE,Melda TÜRKEN,Lütfiye KUZUCU,Gamze TÜRE,Tümay ÖRSEL | 1–3 |
| The Association Between Hepatitis B Virus (HBV)-DNA Levels and Biochemical Markers | Tülin DEMİR,Esra KOÇDEMİR,FİKRİYE MİLLETLİ SEZGİN | 4–7 |
| Performance of Rapid Test in Detection of Anti-HCV in Frozen Sera | Zafer MENGELOĞLU,Özlem BUCAK,MÜCAHİDE ESRA KOÇOĞLU,Tekin TAŞ,ŞEYDA KARABÖRK | 8–10 |
| The Evaluation of Mean Platelet Volume in Hepatitis C Infection | Fatih DEMİRCAN,FARUK KILINÇ,NEVZAT GÖZEL,Banu ŞENATEŞ ERKALMA,Ebubekir ŞENATEŞ | 11–14 |
| Changing Epidemiology of Chronic Hepatitis C in Adana | FERİT KUŞCU,SÜHEYLA KÖMÜR,AYŞE SEZA İNAL,Aslıhan Candevir ULU,Behice KURTARAN,Yeşim TAŞOVA,Berrin ÜNLÜ,Dürdane MIDIKLI,Zehra Doğan TOMUL,Gürkan YILMAZ,Bedia SUNTUR MUTAY,Hasan Salih Zeki AKSU | 15–18 |
| The Role of the Basal Core Promoter (BCP) and Precore Codon 28 Mutations in the Treatment Response to the Pegylated Interferon | ŞÜKRAN KÖSE,Süheyla Serin SENGER,Gülsün ÇAVDAR,Pelin ADAR | 19–22 |
| Evaluation of the Results of Antiviral Therapy in Pregnant Women with Chronic Hepatitis B | AYŞE ERTÜRK,Ekan CÜRE,EMİNE PARLAK,Medine CÜRE CUMHUR,Ayşegül ÇİÇEK ÇOPUR,Figen ŞAHİN KIR | 23–27 |
| Correlation Between Hepatitis B and C Positivity and Rheumatoid Factor Levels in Patients with Rheumatoid Arthritis | SONGÜL ÇİLDAĞ,TAŞKIN ŞENTÜRK | 28–31 |
| Lichenoid Drug Reaction Developing During the Treatment of Recurrent Chronic Hepatitis C | ÇİĞDEM KADER,Emine ÖZEL ÇÖLGEÇEN,Selda SEÇKİN,AYŞE ERBAY | 32–35 |
| A Pregnant Case with Acute Hepatic Failure Treated with Tenofovir | Zeliha TUFAN KOÇAK,Emre VUDALI,Cemal BULUT,SABİTE KACAR | 36–39 |
| Hepatocellular Carcinoma Developing in HIV/HBV Co-Infection: Case Presentation | Ayşe İNCİ,Muzaffer FİNCANCI | 40–42 |